Actualités sur Economy

08.09.2006 – 22:37
sanofi-aventis Group
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(r) (Enoxaparin Sodium Injection) Vs. Unfractionated Heparin (UFH) in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
Paris (ots/PRNewswire) - The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI): An International Randomized Evaluation), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated ...
plus
07.09.2006 – 19:24
Medify Solutions
Medify Solutions Limited Launches MedifyRemote for BlackBerry
Toronto, Canada (ots/PRNewswire) - - Mobile Access to Clinical Data now Available on BlackBerry Devices Medify Solutions Limited (Pink Sheets - MFYS) today announced that its product portfolio will be available on BlackBerry(R) handsets. The MedifyRemote application allows mobile access to patient notes and clinical systems in real time, helping doctors and nurses to provide better, more efficient and more ...
plus
07.09.2006 – 08:05
Sanofi-aventis; Bristol-Myers Squibb
European Commission Expands Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most Severe Type of Heart Attack
Paris (ots/PRNewswire) - - PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission has granted a new indication for the antiplatelet ...
plus
06.09.2006 – 09:32
Pfizer AG
Lipitor More Effective Than Simvastatin in Cutting Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack, New Data Suggests
New York (ots/PRNewswire) - - Heart Disease Patients who Were at a Very High Risk for Having a Second Heart Attack and Took Lipitor 80mg Had a 46 Percent Reduction in the Risk of Experiencing Additional Heart Attacks Compared With Patients Taking Simvastatin - Investigator: 'These data suggest the benefit ...
plus
05.09.2006 – 10:05
Roche Pharmaceuticals
Roche Requests Re-Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Basel, Switzerland (ots/PRNewswire) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re-examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment of pancreatic cancer ...
plus
05.09.2006 – 08:17
Hospital Pitie Salpetriere-Institut du coeur
RIVIERA Registry Identifies Modifiable Predictors of Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention
Barcelona, Spain (ots/PRNewswire) - Results of the multinational, prospective, observational RIVIERA registry (Registry on IntraVenous anticoagulation In the Elective and primary Real world of Angioplasty) announced today at the World Congress of Cardiology 2006- joint meeting of the European Society of ...
plus

05.09.2006 – 00:32
Pfizer AG
New Lipitor Data Published in The Lancet
New York (ots/PRNewswire) - - Lipitor Reduces Risk of Major Cardiovascular Events Such as Heart Attacks in People With Heart Disease and With a Cluster of Other Major Cardiovascular Risk Factors, Often Referred to as Metabolic Syndrome, New Analysis Shows - Heart Disease Patients With Metabolic Syndrome who Took Lipitor 80mg Dose Reduced Their Risk of Major Cardiovascular Events by Nearly 30 ...
plus
04.09.2006 – 08:17
sanofi-aventis Group
New Clinical Data Show Enoxaparin Significantly Reduces the Risk of Repeat Heart Attacks and Stroke in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Barcelona (ots/PRNewswire) - - Results of the PCI-ExTRACT Sub-Study Results of the PCI-ExTRACT-TIMI 25 study announced today at the World Congress of Cardiology-European Society of Cardiology 2006 in Barcelona, showed that among patients with ST-segment elevation myocardial infarction (STEMI) who ...
plus
03.09.2006 – 12:03
Servier
New Study Shows Benefits of Coversyl (R) (Perindopril) in Elderly With Chronic Heart Failure
Barcelona, Spain (ots/PRNewswire) - - Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a number of clinical benefits to elderly people with chronic heart failure according to the results of a study presented at ...
plus
31.08.2006 – 08:01
shaPE Capital AG
euro adhoc: shaPE Capital AG / quarterly or semiannual financial statement / shaPE stays on course
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.08.2006 Pfaeffikon SZ, 31 August 2006 --- For the first six months ending 30 June 2006 shaPEs share price gained 3.2% to CHF 224.00 while the Net Asset Value (NAV) per share decreased by 2.7% to CHF 228.21. The reduced NAV per share relates to ...
plus
21.08.2006 – 15:04
Isotechnika Inc.
Isotechnika Inc. Announces Promising Results From Phase I TAFA93 Trials
Edmonton, Alberta (ots/PRNewswire) - - Isotechnika Inc. announced today promising results from its Phase I TAFA93 trials. TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation. mTOR inhibitors are typically used in combination with ...
plus
17.08.2006 – 13:38
The Alliance for Better Bone Health
Osteoporosis Treatment Now Approved in Europe & US for Men
Paris, France (ots/PRNewswire) - - Male Osteoporosis: Neglected and Under Treated PARIS, France, August 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) this week approved Actonel(R) 35mg (risedronate sodium tablets) for 'treatment to increase bone mass in men with osteoporosis'. This follows the positive outcome in July 2006 of the European application for the additional indication of ...
plus

16.08.2006 – 14:12
Tibotec Pharmaceuticals Ltd.
48 Week Data on Investigational Antiretroviral TMC125 From Tibotec
Toronto (ots/PRNewswire) - - TMC125 a Next-Generation NNRTI Tibotec Pharmaceuticals Ltd. presented 48 week efficacy and safety data on TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 16th International AIDS conference (IAC), AIDS 2006, in Toronto, Canada this week. TMC125 is currently being investigated in phase 3 trials (DUET 1 and 2) in treatment-experienced adult ...
plus
14.08.2006 – 17:04
Boehringer Ingelheim
Tipranavir Achieves Virologic and Immunologic Improvements in HIV-Positive Children at 48-Weeks of Therapy
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
plus
14.08.2006 – 10:18
Roche Pharmaceuticals
Updated International AIDS Society Guidelines Recommend New Goal of Undetectable Viral Load for Treatment-Experienced Patients
Basel, Switzerland (ots/PRNewswire) - - FUZEON Combined With New Protease Inhibitors Provides Best Hope for Patients who Have Been Battling Resistant Virus During the world's largest HIV/AIDS congress in Toronto (XVI International AIDS Conference) new guidelines from the influential International AIDS ...
plus
14.08.2006 – 01:31
Bill & Melinda Gates Foundation
Bill and Melinda Gates: We Need to Put the Power of HIV Prevention in the Hands of Women
Toronto (ots/PRNewswire) - - Joint Keynote at AIDS Conference Highlights Need to Accelerate Research on New HIV Prevention Tools - Especially Microbicides - to Empower Women Bill and Melinda Gates today called upon world leaders to "put the power to prevent HIV in the hands of women" by accelerating the search for microbicides and other new HIV prevention ...
plus
10.08.2006 – 11:03
AM-Pharma B.V.
Dutch Biopharmaceutical Company AM-Pharma Strengthens Intellectual Property Position for Lactoferrin Derived Antimicrobial Peptide hLF1-11
Bunnik, The Netherlands (ots/PRNewswire) - AM-Pharma B.V., a biopharmaceutical company engaged in the pre-clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces the issuance of the patent for one of its lead products, the antimicrobial peptide hLF1-11, ...
plus
09.08.2006 – 07:26
CBMI Canada
Archbishop Desmond Tutu Launches 100,000 Cataract Operations in 100 days
Cape Town, South Africa (ots/PRNewswire) - "We can really do something to change the world," says Archbishop Desmond Tutu. "I think not being able to see is one of the most debilitating disabilities in our world today," Archbishop Tutu said at the launching of Christian Blind Mission's worldwide "100,000 Miracles" campaign at an International Press Conference held ...
plus

07.08.2006 – 16:17
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets - MFYS) Announces Permanent Appointment of Group Company Secretary
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited Today Announced the Appointment of Gayle E. Hanlon, as its Group Company Secretary Effective 1 August 2006. Ms. Hanlon, a US business lawyer representing several German and Swiss corporations in their respective international corporate, commercial ...
plus
04.08.2006 – 15:58
Medify Solutions Ltd.
Medify Solutions Limited - CEO Initial Assessment Statement
Gateshead, England (ots/PRNewswire) - From the 1st July 2006 Ian O'Reilly was appointed the Group CEO of the Medify Solutions (OTC: MFYS) group of companies. One month into the role, O'Reilly provides the following assessment as to the state of the business. "It has been obvious from the outset of my involvement with Medify that massive potential exists for the Company, the products and this emerging market. Having ...
plus
03.08.2006 – 15:47
Medify Solutions Ltd.
Medify Solutions Limited - Announces Results of Strategic Commercial Model Review
Toronto (ots/PRNewswire) - Over the past month, Medify Solutions Limited (OTC: MFYS) has conducted a full and extensive review of its commercial model being operated and going forward in the UK, European and global markets. This exercise has examined the various options that exist in the market, with the prime focus of adopting the one which shows the greatest ...
plus
02.08.2006 – 16:19
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets MFYS) Explains the Sales Potential for UK Remote Access Market
Gateshead, England (ots/PRNewswire) - On the 1st September 2006, Medify Solutions Limited will roll out its 'remote access to patient notes' product, MedifyRemote, to its National Health Service (NHS) customers. The first NHS site, as published previously , will be in Doncaster in the north of England. This ...
plus
02.08.2006 – 15:32
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets MFYS) - Statement
Gateshead, England (ots/PRNewswire) - Due to the number of product sales enquiries from UK based NHS GP practices, Medify Solutions Limited would like to clarify the product availability situation. The first production release of Medify Remote is scheduled to be utilised at Doncaster Central PCT from 1st September 2006. No live GP practice, PCT sales or installations will occur until this date. Confirming the ...
plus
01.08.2006 – 09:04
AstraZeneca GmbH
Time for Change - Aromatase Inhibitors Such as ARIMIDEX(TM) Confirmed Superior to tamoxifen
Macclesfield, England (ots/PRNewswire) - - International Panel of Breast Cancer Specialists Agree: 'With Successful Adjuvant Therapy, Early Breast Cancer is Potentially a Curable Condition.' - ATTN: Health Professional Press - For International Journalists - Not for US Media Today, leading breast cancer experts advised unequivocally that 5 years' ...
plus

28.07.2006 – 17:05
Pfizer AG
Pfizer's Champix(R) Receives Positive Opinion From CHMP for the Treatment of Smoking Cessation
New York (ots/PRNewswire) - - More Than 1.2 Million Europeans Die of Smoking-Related Diseases Each Year; An Estimated US$500 Billion in Global Health-Related Costs by 2010 - Medical Expert: 'Helping smokers quit is one of the most important things a physician can do to improve their patients' overall health and reduce the risk of developing serious ...
plus
28.07.2006 – 16:27
Roche Pharmaceuticals
In the Interests of Patients, Roche Will Consider all Options Following CHMP Opinion on Tarceva in Pancreatic Cancer
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic ...
plus
27.07.2006 – 18:19
PharmaMar
PharmaMar Submits Marketing Authorization Application in Europe for Yondelis(R) In Soft Tissue Sarcoma
Madrid (ots/PRNewswire) - PharmaMar today announces the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for Yondelis(R) (trabectedin) as a treatment for soft tissue sarcomas (STS). The application is based on the results of a randomised, Phase II pivotal study of ...
plus
27.07.2006 – 14:01
Zeltia Group
Zeltia S.A.: Report at 30 June 2006
Madrid, Spain (ots/PRNewswire) - Corporate: - Zeltia performs 1-for-50 bonus issue - Group revenues amounted to 42.5 million euro. - Investment in R&D amounted to 24.4 million euro in the first half of 2006. - The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro. PharmaMar: - Excellent results of Yondelis in myxoid ...
plus
26.07.2006 – 16:52
Medify Solutions Ltd.
Medify Solutions Ltd. (Pink Sheets: MFYS) Announces Latest Business Developments With Oracle and Revenues
Gateshead, England (ots/PRNewswire) - Remote Technology Company Medify Solutions (Pink Sheets: MFYS) is delighted to announce its expansion into the European market with Oracle as business partner, the world's largest enterprise software company. Following the positive collaborative achievements of Medify with ...
plus
26.07.2006 – 10:07
Global Lung Cancer Coalition (GLCC)
Media Reminder - Journalism Awards for Lung Cancer Reporting
London (ots/PRNewswire) - The Tempus Journalism Awards, launched earlier this year by the Global Lung Cancer Coalition (GLCC), is the first global initiative to recognise excellence in lung cancer reporting. There are still two months remaining before judging begins - so please continue to send in your submissions. Remember, entries are invited from journalists whose features, commentaries or programmes on lung ...
plus

Précédent67686970717273747576Suivant